2.635

5.82% +0.145

After Hours: 2.5519 -0.0831 -3.15%

Bio-Path Holdings Inc (BPTH)

Overview News Price History Option Chain Discussions Forecast Stock Split

Bio-Path Holdings Inc stock is currently priced at $2.635, with a 24-hour trading volume of 155.78K. It has seen a +5.82% increased in the last 24 hours and a -30.29% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $2.58 pivot point. If it approaches the $2.70 resistance level, significant changes may occur.

Previous Close:

$2.49

Open:

$2.49

24h Volume:

155.78K

Market Cap:

$4.12M

Revenue:

Net Income/Loss:

$-16.08M

P/E Ratio:

-1.1923

EPS:

-2.21

Net Cash Flow:

$-11.54M

1W Performance:

-37.26%

1M Performance:

-30.29%

6M Performance:

+320.52%

1Y Performance:

+95.24%

1D Range:

$2.35

$2.75

52W Range:

$0.32

$7.6699

Bio-Path Holdings Inc Stock (BPTH) Company Profile

Name

Bio-Path Holdings Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

832 742 1357

Address

4710 Bellaire Boulevard, Suite 210, Bellaire, TX

Employee

Twitter

Next Earnings Date

2024-05-10

Latest SEC Filings

BPTH's Discussions on Twitter

Bio-Path Holdings Inc Stock (BPTH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-11-21	Initiated	ROTH Capital	Buy
Nov-13-17	Reiterated	H.C. Wainwright	Buy
Aug-10-16	Reiterated	Maxim Group	Buy
Apr-18-16	Initiated	Rodman & Renshaw	Buy
Jun-02-14	Resumed	Maxim Group	Buy
May-09-14	Initiated	Maxim Group	Buy

View All

Bio-Path Holdings Inc Stock (BPTH) Latest News

Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire Inc.

Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study

Zacks Investment Research

Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire Inc.

Bio-Path Holdings Inc Stock (BPTH) Financials Data

Bio-Path Holdings Inc (BPTH) Net Income 2024

BPTH net income (TTM) was -$16.08 million for the quarter ending December 31, 2023, a -15.94% decrease year-over-year.

Bio-Path Holdings Inc (BPTH) Cash Flow 2024

BPTH recorded a free cash flow (TTM) of -$11.54 million for the quarter ending December 31, 2023, a +23.73% increase year-over-year.

Bio-Path Holdings Inc (BPTH) Earnings per Share 2024

BPTH earnings per share (TTM) was -$34.43 for the quarter ending December 31, 2023, a +9.68% growth year-over-year.

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.